antiplatelet drugs, aspirin 300 mg/d
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 1997 May 31;349(9065):1569-1581 Randomized Controlled Trial, Multicenter Study
IN stroke, ischemic, cerebral infarction, thrombotic The Use of
antiplatelet drugs, aspirin 300 mg/d
As Treatment, Acute
Is better Than
placebo or unfractionated heparin (UFH), either low or full-dose
To reduce at 14 days recurrent ischaemic strokes (2.8% aspirin VS 3.9% placebo) or death plus non-fatal recurrent stroke (11.3% aspirin vs 12.4% placebo)